Drug
TTI-101
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
TTI-101 inhibits (or prevents the activity of) STAT3 (signal transducer and activator of transcription 3), a protein that, when activated, plays a key role in the development of fibrosis in patients with IPF. TTI-101 comes in a pill that is taken by mouth twice a day.
Study Purpose
The REVERTIPF clinical trial is evaluating the safety and effectiveness of TTI-101 alone or with nintedanib (OFEV®) in adults with idiopathic pulmonary fibrosis (IPF). The clinical trial will test 3 different doses of TTI-101 compared to a placebo, which looks like but does not contain TTI-101.